Key result
A 65-year-old male with primary myocardial diffuse large B cell lymphoma experienced disease progression after 6 cycles of R-CVP chemotherapy and transitioned to palliative care.
Why the study?
Primary myocardial involvement of diffuse large B-cell lymphoma is extremely rare, accounting for 0.5% of all lymphomas.
Case Report (n=1)
Primary myocardial diffuse large B cell lymphoma is an extremely rare cause of acute cardiac tamponade that can be refractory to standard R-CVP chemotherapy.
Answers are grounded in this paper and cite their sources.
Indicates possible R-CVP refractoriness in primary myocardial DLBCL; leaves open optimal regimens for this rare entity.
Primary myocardial involvement of Diffuse Large B-Cell lymphoma is extremely rare, accounting for 0.5 % of all lymphomas. We report a 65-year-old male, presenting with an acute cardiac tamponade, which was drained. A pericardial window with myocardial biopsy was carried out, disclosing a diffuse large B cell lymphoma. He received 6 cycles of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP), without response. Finally, a palliative chemotherapy with gemcitabine plus oxaliplatin was prescribed.
No takes yet. Share an insight, caveat, or question.
Lara et al. (2021) conducted a case report in Primary myocardial diffuse large B cell lymphoma (n=1). R-CVP chemotherapy was evaluated on Tumor response. A 65-year-old male with primary myocardial diffuse large B cell lymphoma experienced disease progression after 6 cycles of R-CVP chemotherapy and transitioned to palliative care.
Synapse has enriched 10 related papers. Consider them for comparative context: